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ABSTRACT
The authors present the current state of knowledge about the long term sequelae of the common travel-
-related infections associated with immunological dysregulation. Travellers’ diarrhoea, chikungunya and 
dengue are common in travellers and protracted manifestations such as post-infectious irritable bowel 
syndrome (travellers’ diarrhoea), arthritis (chikungunya) or post-dengue syndrome may be more prevalent 
than previously thought. Attention should be paid to active prevention of the infections during travel, 
especially when an effective treatment against long-term sequelae has not been established. Further 
studies should be designed in order to determine the interactions between the host, the environment and 
the pathogens, as well as to identify the prognostic factors for developing long-term manifestations after 
infections in a large group of travellers.
(Int Marit Health 2018; 69, 3: 207–212)
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TRAVELLERS’ DIARRHOEA
DEFINITION, EPIDEMIOLOGY, CLINICAL  
SYMPTOMS 
Travellers’ diarrhoea (TD) is one of the most common 
travel-associated diseases. Virtually everyone experienced 
diarrhoea at least once in their lifetime, in particular 
while travelling through developing countries. Acute TD 
has been defined as passage of ≥ 3 unformed stools 
within a  24-hour period. The signs of enteric infection 
may include abdominal pain, nausea, vomiting, cramping, 
flatulence, fever, stool urgency, bloody or mucous stool, 
or tenesmus [1].
The risk of TD depends mostly on the destination; the 
highest risk prevails in Asia, the Middle East, Africa, Central 
and South America [2]. The majority of the individuals who 
develop acute diarrhoea will have self-limiting symptoms 
lasting < 5 days, even without any treatment. Unfortunately, 
a portion of the patients will develop prolonged symptoms 
lasting for years [3]. 
LONG-TERM SEQUELAE OF THE TRAVELLERS’ 
DIARRHOEA 
Over 55 years ago, Chaudhary and Truelove [4] present-
ed a series of 130 irritable bowel syndrome (IBS) cases and 
demonstrated that 26% of these patients associated the 
onset of IBS with an episode of dysentery [5]. Numerous 
studies conducted since then confirmed that, depending on 
the study, approximately 4% up to even 36% of IBS cases 
develop after a bout of infectious diarrhoea. In such event, 
the disease is considered post-infectious IBS (PI-IBS). The 
duration of the symptoms may vary and may even exceed 
12 years [6]. PI-IBS appears to be caused by a non-specific 
response to a prior infection which may have been caused 
by a variety of enteric pathogens, including Campylobacter 
spp., Salmonella spp., and diarrhoeagenic strains of Esch-
erichia coli including ETEC, Shigella spp., Cryptosporidium 
spp. or Giardia spp. [7–11]. 
Given the total number of travellers and the frequen-
cy of diarrhoea while traveling, the global population of 
patients suffering from PI-IBS may be significant. Irritable 
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bowel syndrome is one of the most common functional 
gastrointestinal disorders in the world [12], causing illness 
in 10–15% of the western populations [6, 13]. PI-IBS is 
diagnosed according to the Rome IV criteria, with the addi-
tional criterion of onset following an acute infectious gas-
troenteritis characterised by two or more symptoms such 
as fever, vomiting, diarrhoea, and a positive stool culture 
result [14, 15]. Therefore, PI-IBS and IBS have similar clin-
ical features, but the former is more likely to occur in the 
persons who travel [6]. 
The risk factors for developing PI-IBS include genetic, 
physical, psychosocial and bacterial factors. One of the 
strongest predictors is the duration and severity of the initial 
infection [16, 17]. Compared to the patients with diarrhoea 
lasting shorter than one week, subjects with symptoms last-
ing > 3 weeks have been determined to have an 11-fold in-
crease in the risk of developing PI-IBS [16]. Younger age and 
age-related more adventurous dietary habits, pre-existing 
psychological disorders such as anxiety, major depression, 
sleep disorders, hypochondriasis, adverse life events in the 
preceding months, tobacco smoking, elevated body mass 
index, alcohol abuse, and stress, are among the suspected 
or established PI-IBS risk factors [5, 6, 16, 18–23]. 
Some of the researchers have suggested an associa-
tion between the type or species of the infecting pathogen 
and the risk of developing PI-IBS but others have found no 
such relation [16, 24]. The most highly suspected species 
include the LT-producing ETEC, Providencia spp. [18], Cam-
pylobacter spp. [25], Salmonella spp. [26] and Shigella spp. 
[7, 24]. In the majority of TD cases it is difficult, however, to 
determine the responsible pathogen, as many of the cases 
occur where the traveling patient has no ready access to 
medical care or a medical laboratory. 
Further risk factors include inflammation, serotonin pro-
duction, mast cells activation, cytokine-mediated response, 
changes in the enteric nerves and altered microbiome 
in the digestive tract [19]. Patients with PI-IBS probably 
also have persistent mucosal immunologic dysregulation 
with altered intestinal permeability and motility which can 
lead to chronic intestinal symptoms [5]. They also appear 
to have higher intraepithelial lymphocyte and the lamina 
propria lymphocyte counts [8]; also, increased numbers of 
mucosa mast cells have been found in many PI-IBS as well 
as IBS-D patients [7, 27, 28]. The release of the mediators 
from mast cells probably contributes to the visceral hyper-
sensitivity by activating the enteric afferent nerves [29, 
30]. Among the cytokines, interleukin-1 beta is a crucial 
pro-inflammatory factor, and its concentration has been 
demonstrated to be increased in the terminal ileum and the 
recto-sigmoid colon of the PI-IBS patients [7] as well as in 
rectal biopsies of the patients who had PI-IBS [9]. Interleu-
kin-6 is increased in both the IBS and depressed patients, 
showing the interesting correlation between psychological 
and infectious factors [31].
Before the recognition of PI-IBS, the main concern in the 
management of travellers’ diarrhoea was the alleviation of 
clinical symptoms to prevent inconvenience and compli-
cations while travelling [6]. It is very important to ensure 
that patients understand the mechanism of PI-IBS and 
that although they are to improve, the symptoms may be 
prolonged and recur even for some years [19]. Patients with 
abdominal pain and anxiety may be offered mild anxiolytics 
[19]. The symptoms of diarrhoea and stool urgency respond 
well to loperamide [19].
The increasing understanding of the mechanism and 
pathophysiology of PI-IBS allows the researchers to attempt 
novel treatment options such as prednisolone [32], ketotifen 
(a mast cell stabilizer), mesalazine, alosetron, ramosetron 
or ondansetron [19]. In general, the treatment of PI-IBS is 
similar to that of non-PI-IBS. In 2005, Hungin et al. [33] 
reported that only 14% of the patients with IBS were com-
pletely satisfied with the effects of their therapy. Therefore, 
it should be emphasized that every effort must be made to 
prevent the disease where possible [5]. 
CHIKUNGUNYA 
DEFINITION, EPIDEMIOLOGY, CLINICAL SYMPTOMS 
Chikungunya virus (CHIKV) infection is caused by an 
arbovirus of the Alphavirus genus transmitted to humans 
by the Aedes mosquitos. Outbreaks have been recorded in 
Africa, Europe, Asia, as well as in the regions of the Pacific 
and Indian Oceans. In 2013, CHIKV was registered in the 
Americas for the first time [2]. During the acute stage of the 
disease, the patients develop fever, arthralgia, joint stiffness 
and joint swelling. Infection has usually an uncomplicated 
course, but a prolonged and frustrating arthralgia persists 
in a significant fraction of the patients, sometimes for years. 
LONG-TERM SEQUELAE OF CHIKUNGUNYA
Arthralgia is one of the typical symptoms in CHIKV infected 
patients. Unfortunately, the pain does not always pass once 
the acute stage of the infection, but it can last for months or 
even years. Depending on the research source, the symptoms 
continue in 32% to 70% of patients [34–37]. The time of the 
follow-up was between 4 months and 6 years [34].  
In 1984, Brighton and Simson [38] described the 
post-chikungunya destructive polyarthritis in South Africa. 
The next step in understanding this phenomenon was taken 
during the outbreaks on the Reunion Island and in India. As 
many as 17% to 84% patients reported long-lasting pain, dis-
ability, muscle pain, impaired quality of life and the need for 
extensive treatment [34]. The spectrum of post-chikungunya 
symptoms also includes tendinitis, tenosynovitis, plantar 
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fasciitis, carpal tunnel syndrome, polyarthralgia, rheumatoid 
arthritis, and psoriatic arthritis [39–41]. The duration of 
symptoms may exceed 33 months. In case of relapse, the 
pain is often observed in the same locations [34].
Among the risk factors associated with post-chikungunya 
polyarthritis, older age is one of the more frequently reported 
[34]. The duration of the initial acute stage of the disease 
is also important: during an outbreak on the Reunion Is-
land, 17% of the patients in whom the acute stage was 
≤ 14 days suffered from chronic symptoms and if the stage 
was > 14 days, chronic symptoms were seen in 84% of the 
patients [36, 42]. 
The comorbidities were reported by many patients, in 
some studies by as many as 60%, they included degener-
ative disc disease (52%), arthritis (34%) and depression 
(23%) [34]. 
The probable mechanism of persistent symptoms is 
the activation of the immune system by the viral load in 
the acute stage of the CHIKV infection. It triggers the pro-
duction of interferons, and monocytes and macrophages 
are the main target cells for CHIKV. Examination of biopsy 
specimens detected that CHIKV can hide in tissues and 
provoke tissue damage [43].
Post-chikungunya treatment should be initiated with 
analgesics, physiotherapy and local therapy. Other treat-
ment methods may also be considered, e.g. a short-course 
of corticosteroids or nonsteroidal anti-inflammatory drugs. 
Disease-modifying anti-rheumatic drugs have been docu-
mented to control the inflammatory process and to prevent 
bone erosions. If the resistance to or dependence on cor-
ticosteroids is observed, the probability of chronic post-in-
fection inflammatory rheumatism is high [44]. Probable 
resistance to or dependence on corticosteroids beyond the 
third month after the disease onset is highly evocative of 
post-chikungunya chronic inflammatory rheumatism. This 
finding suggests early treatment with disease-modifying 
anti-rheumatic drugs to control the inflammatory process, 
to prevent bone erosions, and to prevent the inevitable side 
effects of prolonged corticoid therapy [44]. In some patients, 
tricyclic antidepressants, tramadol and antiepileptic drugs 
may be considered, especially in neuropathic pain [45]. 
Because the effect of the treatment is uncertain, the 
patient should be made aware of the mechanism of the 
disease; this could help them accept the disease and facil-
itate the recovery. 
DENGUE
DEFINITION, EPIDEMIOLOGY, CLINICAL SYMPTOMS 
Dengue is a  viral disease transmitted by the Aedes 
mosquitos. Dengue virus (DENV) infection is endemic in the 
tropical and subtropical countries. During the last decades it 
has emerged as a serious international public health threat 
as almost half of the world’s population are now at risk of in-
fection, including European basin of the Mediterranean Sea 
(Croatia, France) [46]. Any of the five serotypes (DENV-1– 
–DENV-5) of the dengue virus can produce a plethora of 
symptoms, ranging from an asymptomatic infection to a se-
vere, life-threatening disease. 
Dengue is characterised by high fever, chills, severe 
headache, skin rash and fatigue. The disease is usually 
benign and self-limiting, but complications may occur, with 
mortality rate approaching 5%. In the recent years, persist-
ing post-dengue symptoms have been described. 
LONG-TERM SEQUELAE OF DENGUE 
A  persistent and incapacitating post-infectious fa-
tigue syndrome might be associated with a number of 
infectious diseases, such as mononucleosis, Lyme dis-
ease, Q fever or Epstein-Barr virus infection but also with 
dengue. Following the acute phase of the illness, patients 
may suffer from long-term fatigue manifestations. They 
describe these symptoms as a  sense of chronic ex-
haustion that decreases their capacity for physical and 
mental work [47]. 
Depending on the study, 25% to 50% of the patients re-
port post-dengue symptoms [47, 48]. No clinical signs were 
observed in the group of asymptomatic dengue infection 
with only a serologic proof of the infection. The time of dura-
tion of post-dengue symptoms was up to 2 years. The clinical 
manifestations reported by the patients through the time 
of observation for 2 years after the acute phase of dengue 
infection included hand weakness, muscle pain, asthenia, 
arthralgia, general malaise, retroocular pain, arthropathy, 
irritability, palpitations, memory impairment, headache, 
vomiting, nausea, dizziness, anorexia, alopecia, rash, vagi-
nal bleeding, diarrhoea, gingivorrhagia. The majority of the 
analysed patients had a history of more than one previous 
dengue infections [48].
There are a number of risk factors which can be at-
tributed to the presence of long-term post-dengue sequel-
ae. The majority of them are associated with the immu-
nological dysregulation. One of the studies identified sex 
as a risk factor, with clinical manifestations being more 
persistent in women than in men (96.7% vs 36.7%) [48]. 
In another study, female sex, advanced age, the presence 
of chills, and the absence of rash were associated with 
the post-dengue fatigue symptom. There was no signif-
icant correlation between dengue severity and fatigue 
[47]. As stated above, dengue infection without clinical 
manifestations, diagnosed based on the serological tests 
results only, was not associated with clinical sequelae. It 
suggests that the infection per se is not a trigger for the 
immunological dysregulation.  
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The phenomenon of antibody-enhancement has been 
well described in the pathogenesis of dengue virus infection. 
Non-neutralizing antibodies circulating in the serum of the 
patients enhance viral entry through the Fc receptor and 
worsen the course of infection [49]. An increased expression 
of Fc activating receptors on the monocytes and macro-
phages is associated with an increase in the production 
of inflammatory cytokines [50]. The following autoimmune 
markers were assessed in a subset of asymptomatic indi-
viduals: complement factors C3/C4, rheumatoid factor (RF), 
C-reactive protein (CRP), antinuclear antibodies (ANA), and 
immune complexes (IC). Persistent clinical manifestations 
were also associated with high IgG titres. On the other hand, 
the predominant neurological clinical symptoms such as 
joint, muscle or bone pain showed no statistically important 
correlation with the IgG titres [48]. In some patients with 
persistent post-dengue symptoms, an increased level of 
CRP was detected. It may suggest a non-degenerative, im-
mune-mediated process that further enhances the damage. 
It can be a result of the presence of interleukin-6 or interleu-
kin-1, interferon a, b and g, and tumour necrosis factor [51], 
possibly released as a  result of the persistent activation 
of Fc-gamma-RIIa on the neutrophils, macrophages, and 
dendritic cells [52]. An overproduction of cytokines such 
as C3a and C5a results in an immune-mediated damage 
to the endothelial cells [47]. Seventy-six per cent of the 
individuals with persistent post-dengue clinical symptoms 
showed alterations in the immunological markers such as 
C3 and C4 complement factors, RF, ANA, IC, and CRP [48].
No effective treatment method of post-dengue syndrome 
has yet been developed. 
Dengue may also cause permanent neurological or oc-
ular damage, including stroke [53, 54], parkinsonism [55], 
myelitis [56], AQP4-antibody-related neuromyelitis optica 
spectrum disorder [57, 58], necrotising scleritis [59], den-
gue-associated maculopathy [60], outer retinal damage 
[61], or glaucoma [62]. 
CONCLUSIONS
Genetic and environmental factors such as acute viral 
or bacterial infection may induce transient autoimmune 
responses. Travellers’ diarrhoea, chikungunya and dengue 
infection are common in travellers and their post-infec-
tious manifestations may be more prevalent than previously 
thought. There are many patients with a history of travel 
who report clinical symptoms and a significant percentage 
of those-patients may have acquired an infection while 
travelling. They seek diagnosis, but an active infection is 
almost never detected, and thus effective therapeutic op-
tions are limited.
Attention should be paid to active prevention measures 
during travel, especially when an effective treatment against 
long-term sequelae has not been established. Physicians 
and public health authorities should also be prepared to 
deal with and manage patients with post-infectious man-
ifestations not only in the epidemic areas, but also in the 
group of returning travellers.
Further studies should be designed in order to determine 
the interactions between the host, the environment and 
the pathogens, as well as to identify the prognostic factors 
for developing long-term manifestations after infections in 
a larger population of travellers. It is yet to be determined 
whether intensive and early treatment of tropical infec-
tions would minimise the occurrence the post-infectious 
symptoms. 
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